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Propolis, a resinous compound produced by Apis mellifera L. bees, is known to possess a variety of biological activities and is
applied in the therapy of various infectious diseases. The aim of this study was to evaluate the in vitro antifungal activity of
propolis ethanol extract (PE) and propolis microparticles (PMs) obtained from a sample of Brazilian propolis against clinical yeast
isolates of importance in the vulvovaginal candidiasis (VVC). PE was used to prepare the microparticles. Yeast isolates (n = 89),
obtained from vaginal exudates of patients with VVC, were exposed to the PE and the PMs. Moreover, the main antifungal drugs
used in the treatment of VVC (Fluconazole, Voriconazole, Itraconazole, Ketoconazole, Miconazole and Amphotericin B) were
also tested. Minimum inhibitory concentration (MIC) was determined according to the standard broth microdilution method.
Some Candida albicans isolates showed resistance or dose-dependent susceptibility for the azolic drugs and Amphotericin B. Non-
C. albicans isolates showed more resistance and dose-dependent susceptibility for the azolic drugs than C. albicans.H o w e v e r ,a l l
of them were sensitive or dose-dependent susceptible for Amphotericin B. All yeasts were inhibited by PE and PMs, with small
variation, independent of the species of yeast. The overall results provided important information for the potential application of
PMs in the therapy of VVC and the possible prevention of the occurrence of new symptomatic episodes.
1.Introduction
Vulvovaginal candidiasis (VVC) is a disease caused by abnor-
mal growth of yeast-like fungi in the mucosa of the female
genitaltract,classiﬁed by the World HealthOrganization as a
sexually transmitted disease of frequent sexual transmission
[1]. VVC is caused mainly by the genus Candida, the major
agentbeingCandidaalbicans,andtheprevalenceofthisyeast
can reach 85–95% [2]. Moreover, studies have shown the
increasinginfectionsbynon-C.albicansspecies(C.tropicalis,
C. glabrata, C. krusei, C. parapsilosis, C. pseudotropicalis,
C. lusitaniae)i nV V C[ 3, 4]. Because the disease strikes
millions of women annually, leading to great discomfort,
interfering with sexual and aﬀective relations and impairing
work performance, it has been considered an important
worldwide public health concern [2]. VVC is the ﬁrst cause
of vulvovaginitis in Europe and the second in the USA
and Brazil. It represents 20–25% of the vaginal discharges
of infectious nature. It is estimated that about 75% of the
adult women show at least one episode of VVC during their
lifetimes, 40–50% of those will experience new surges and
5% will reach the recurrent character (RVVC), deﬁned as the
occurrence of four or more symptomatic episodes in a one
year interval [4].
In recent years, drug-resistance to antifungal agents and
optimizing therapy of Candida infections have been broadly
focused [5]. Moreover, the therapeutic arsenal available for
the treatment of fungal infections is quite restricted, being
limited to polyenic and azolic antifungal chemicals [6, 7].
For the treatment of VVC, nystatin (cream or vaginal ovule)
has been used for almost three decades, but therapeutic fails
were observed [8, 9]. Amphotericin B would be an excellent
therapeutic resource because of its high eﬃcacy, but has
showed high toxicity [9]. The azolics are drugs that inhibit
the synthesis of ergosterol, an important component of the
fungal cell membrane [7]. Of these, Fluconazol (FLU) is
one of the most used in VVC, but, in addition to its high
cost, it has been reported the development of resistance2 Evidence-Based Complementary and Alternative Medicine
of C. albicans and non-C. albicans yeasts against this drug
[2]. These facts make the management of patients with
VVC and RVVC diﬃcult and put into evidence the need
of searching for new, eﬀective, safe, low-cost antifungal
alternatives against this pathology.
Natural products have been traditionally used in the
treatment of diseases because they are source of many active
compounds. Propolis, a strongly adhesive resinous com-
p o u n dp r o d u c e db yApis mellifera L. bees, has demonstrated
important antimicrobial activity and has been used to treat
inﬂammatory, bacterial and fungal diseases [10–14]. With
complexchemicalcomposition,typicallyconsistingofwaxes,
resins, water, inorganics, phenolics and essential oils, the
exact composition of propolis is dependent upon the source
plant(s) [10, 15–20]. Thus, Brazilian propolis has been the
subject of intensive research over the last few decades [21,
22]. It has been sub-divided into four types based on the
association of ethanol extracts of Brazilian samples with the
levels of bioactive compounds [23]. Brazilian propolis is
known for its antifungal activities [12, 13, 24].
Furthermore, propolis ethanol extract (PE), alone or
incorporated in another dosage form, is commonly utilized
as therapeutics [10, 11, 25]. However, the high ethanol con-
centration is a disadvantage of PE, resulting in diﬃculties on
the administration and incorporation in some dosage forms
like vaginal ointments [11, 25]. The patient compliance to
the therapeutics is committed too. Studies have shown that
it is possible to obtain microparticles containing propolis
without the high ethanol concentration and with prolonged
release of propolis [11, 12, 26].
Despite this discovery and the problem of VVC, no
studies have been carried out to determine the inhibitory
eﬀect of Brazilian propolis microparticles (PMs) against
vaginal pathogens. Thus, the aim of this study was to prepare
and evaluate the in vitro antifungal activity of PMs against
yeasts (C. albicans and non-C. albicans)o fV V Ci m p o r t a n c e .
2. Methods
2.1. Chemicals and Reagents. Type A gelatin, Royal (S˜ ao
Paulo, Brazil), was used without further puriﬁcation. FLU
and Voriconazole (VORI) were obtained from Pﬁzer Inc
(New York, NY, USA). Itraconazole (ITRA), Ketoconazole
(KETO) and Miconazole (MICO) were purchased from
Janssen Pharmaceutical (Titusville, NJ, USA) and Ampho-
tericin B (AMB) was obtained from Squibb Pharmaceutical
(Princeton, NJ, USA). Furthermore, Sabouraud dextrose
broth (SDB), Sabouraud dextrose agar (SDA) and Mueller
Hinton broth (MHB) were purchased from Difco (Detroit,
USA). CHROMagar Candida was purchased from Probac
(Paris, France) and RPMI-1640 medium from Sigma (Stein-
heim, Germany). All other chemicals and solvents were of
analytical grade and purchased from Merck (Darmstadt,
Germany).
2.2. Propolis Sample. The Brazilian propolis sample was
collected from hives of Apis mellifera L. bees at the
Iguatemi Experimental Farm, which belongs to the State
University of Maring´ a (FEI-UEM), Maring´ a, Paran´ a state,
Brazil. The apiary was located north-west of Paran´ a State,
inside a eucalyptus reserve surrounded by native forest with
a predominance of Baccharis dracunculifolia (Asteraceae).
Propolis collection was carried out both inside and outside
the hive, with the surfaces being scraped smoothly with a
wooden chisel. The samples were combined into a single
batch, packed in a sealed plastic bag and stored at –20◦C.
2.3. Preparation and Characterization of PE. Propolis was
powdered and the PE was prepared with propolis/ethanol
ratio of 30/70 (w/w) by turbo extraction [11]. Exactly
weighted 10g of PE was concentrated on water bath (100◦C)
with eventual shaking. The concentrated material was dried
on the Ohaus-MB 200 infrared analytical balance (Pine
Brook, NJ, USA) at 110◦C and the result was presented as
“dryness residue” (DR) value. Six replicates were carried out
toestimatetheinherentvariabilityofeachthedetermination.
The total phenol content (TPC) of PE was determined
by the Folin-Ciocalteau method [20]. PE was mixed with
6mLoftheFolin-Ciocalteauand6mLof20%Na2CO3.After
2h, the absorbance was measured by Shimadzu UV-1650PC
spectrophotometer (Tokyo, Japan) at wavelength of 760nm.
A calibration curve with solutions of gallic acid was used as
reference. TPC was expressed as percentage of total phenolic
substances in PE and corresponds to mean of six replicates.
2.4. Preparation and Characterization of PMs. PE was dis-
persed in a gelatin solution at 20◦C through the dripping
technique using a syringe of 10mL, and with magnetic
agitation by 30min [11]. The amount of gelatin utilized was
a function of the PE DR. The ratio gelatin/PE DR was 6/1
(w/w). The ﬁnal dispersion was spray-dried in a B¨ UCHI
Mini Spray Dryer model B-191 (B¨ uchi, Flawil, Switzerland)
through the nozzle, using the following conditions: inlet
temperature of 160◦C; feed rate of 6%; aspiration of 80%;
pressure of 3%; mannitol 20% (w/w). The resultant dried
product was collected and stored in a vacuum desiccator at
room temperature.
The mean particle size and size distribution of PMs
were assessed by a CARL ZEISS optical microscope and
the CARL ZEISS AxioVision Image Analysis System (CARL
ZEISS,Germany).Particleswereplacedonglassslideandthe
size measurements of microparticles were performed using
Feret’s diameter as parameter. A total of 2000 PMs were
measured and the particle size distribution was estimated.
Moreover, the shape and surface of produced microparticles
were investigated by scanning electron microscopy (SEM).
The spray-dried products were ﬁxed on supports and coated
with gold-palladium under argon atmosphere using a gold
sputter module in a high-vacuum evaporator. Samples were
then observed with SHIMADZU SS550 scanning electron
microscope (SHIMADZU, Tokyo, Japan) at 15kV.
Theamountofpropolisincorporatedintomicroparticles
was determined by the Folin-Ciocalteau method [20], with
minor modiﬁcations. PMs were mixed with 6ml of the
Folin-Ciocalteau and 6mL of 20% Na2CO3.A f t e r2 h ,
the absorbance was measured by Shimadzu UV-1650PC
spectrophotometer (Tokyo, Japan) at wavelength of 760nm.Evidence-Based Complementary and Alternative Medicine 3
A calibration curve with solutions of gallic acid was used as
reference. TPC was expressed as percentage of total phenolic
substances in PMs and corresponds to mean of six replicates.
The propolis encapsulation eﬃciency was calculated by
comparing the TPC of the PE with that of the PMs.
2.5. Antifungal Assays. A total of 89 yeast strains, obtained
from vaginal exudates of the VVC patients, were tested: 58
C. albicans and 31 non-C. albicans (17 C. glabrata,0 1C.
tropicalis,0 8C. guilliermondii and 05 C. parapsilosis). These
yeast cells were isolated and identiﬁed in 2007 [27, 28]a n d
are part of a yeast bank from the Laboratory of Medical
Mycology at the State University of Maring´ a (Maring´ a, PR,
Brazil). The isolates were stored in SDB with 10% of glycerol
at –20◦C after identiﬁcation.
The yeast isolates were tested by Clinical Laboratory
Standards Institute reference broth, microdilution method
for FLU and ITRA [29], with modiﬁcations for others drugs
and for PE and PMs [30]. Stock solutions of drugs were
prepared at 10 times the strength of ﬁnal concentration and
diluted with RPMI 1640, with l-glutamine, without bicar-
bonate, supplemented with 2% dextrose and buﬀered to pH
7.0 with 0.165 N-morpholinopropanesulfonic acid to obtain
twice the ﬁnal concentration. Yeast isolates were grown on
SDA for 48h, at 37◦C. The density of suspension of cells
in sterile distilled water was adjusted by spectrophotometer
to a ﬁnal transmission of 90%, at a wavelength of 530 nm.
Suspension was made with a 1:50 dilution in sterile distilled
water, followed by a 1:5 dilution in RPMI medium to obtain
two times the ﬁnal concentration. The test was performed
in sterile, ﬂat-bottom 96-well microtiter plates. Volumes
of 100µL of twice the dilutions and 100µL of twice the
inoculum were dispensed into wells. Inoculum size averaged
between 0.5 and 2.5 × 103 cells mL–1. For the PE and PMs
test, 100µL aliquots of MHB were distributed from column
2t o1 1m i c r o t i t e rp l a t e s .
PMs were diluted (1.0g of PMs, 1.0mL of ethanol
and 4.0mL of sterile distilled water). PE or PMs, in
100µL aliquots, were added to columns 1 and 2 of the
microplate and from column 2 onwards the serial dilution
was performed at a ratio of 2 until the 10th well (dilutions
of 1:1024). In this way, the concentrations of the tested PE
ranged from 17.19 to 1100.63µgmL –1 of TPC, and from
10.86 to 5570.49µgmL –1 of TPC in PMs.
Foreachisolate,negative(onlyRPMIorMHB)andposi-
tive controls (RPMI/MHB and inoculate, without antifungal
addition) of growth and the possible action of the diluent
(alcohol and inoculate) were included. In each plate a strain
of C. parapsilosis (ATCC 22019) was included as reference
yeast. The plates thus mounted were incubated at 35◦Cf o r
48–72h with daily monitoring. After 48h the reading of the
drug test was performed in microplate reader (Asys Hitech
GmbH, Eugendorf,Austria),andafter72h the reading ofthe
PEandPMswasmadethroughvisualcomparison,bymirror
reﬂex.
The minimum inhibitory concentrations (MICs) of
azoles were deﬁned as the ﬁrst well with a signiﬁcant
growthreduction(∼50%)whencomparedtothatofpositive
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Figure 1: Size distribution of propolis microparticles (PMs):
size frequency distribution (bars) and size cumulative frequency
distribution (line). The particle size class interval is 2.5µm.
control. In the case of AMB, it was deﬁned as the lowest
concentration capable of inhibiting 90% of the growth.
Endpoints for antifungal agents: isolates with MIC between
16 and 32µgmL –1 for FLU, 0.25 and 0.5µgmL –1 for ITRA,
KETOandMICOand2µgmL –1 forVORIhadreduceddose-
dependent susceptibility. Isolates with MICs ≤8µgmL –1 for
FLU, ≤0.125µgmL –1 for ITRA, KETO and MICO, and
≤1µgmL –1 for AMB and VORI, were susceptible. MICs
≥ 64µgmL –1 for FLU, ≥1µgmL –1 for ITRA, KETO and
MICO, ≥4µgmL –1 for VORI and ≥2µgmL –1 for AMB, were
resistant [6, 8].
For PE and PMs, the results of the MIC were considered
relativetoTPCandweredeterminedasthelowestconcentra-
tion of total phenols capable of inhibiting 100% of the yeast
growth, as compared to its respective positive control [13].
3. Results
3.1. Characterization of PE. Dryness residue of PE was 18.43
± 0.17% with 0.92% of relative standard deviation (RSD).
TPC was 7.28 ± 0.12% and its RSD was 1.70%.
3.2. Characterization of Microparticles. PMs were easily
obtained by spray-drying technique [11]. Measurements of
microparticles showed a narrow size distribution (Figure 1)
and the mean particle size of 4.06µm. Figure 2 indicated
that microparticles were in ﬁne spherical shape with smooth
surfaces, with a low number of coalesced microparticles
and low agglomeration determined by SEM. The amount of
total phenolics compounds in PMs was 0.97 ± 0.04% and
the propolis encapsulation eﬃciency into microparticles was
78.51 ± 2.81% (n = 6).
3.3. Antifungal Assay. Table 1 shows the interpretation of
the MIC results for antifungal drugs as for sensitivity,
dose-dependent susceptibility and resistance. Some isolates
of C. albicans showed resistance for ITRA, KETO, MICO,
and AMB (10.3, 25.8, 3.5 and 1.7%, resp.) and dose-
dependent susceptibility for all azolics. Isolates of non-
C. albicans showed more resistance and dose-dependent
susceptibility than C. albicans. Tested isolates of non-C.4 Evidence-Based Complementary and Alternative Medicine
Table 1: Interpretation of the results of MIC for antifungal drugs against vaginal yeasts of C. albicans (n = 58) and non-C. albicans (n = 31).
Candida albicans Non-Candida albicans
Antifungals Sa DDSb Rc S DDS R
n % n % n % n % n % n %
FLU 55 94.8 3 5.2 — — 26 83.9 5 16.1 — —
ITRA 48 82.8 4 6.9 6 10.3 18 58.1 4 12.9 9 29.0
KETO 20 34.5 23 9.7 15 25.8 9 29.0 7 22.6 15 48.4
MICO 42 72.4 14 24.1 2 3.5 6 19.4 20 64.5 5 16.1
VORI 57 98.3 1 1.7 — — 30 96.8 1 3.2 — —
AMB 57 98.3 — — 1 1.7 31 100.0 — — — —
DDS, dose-dependent susceptibility; R, resistant.
aS:IsolateswithMIC≤8 µgmL –1 forFLU, ≤0.125µgmL -1 forITRA,KETO,andMICO,and ≤1µgmL –1 forAMBandVORI, bDDS:Endpointsforantifungal
agents: isolates with MIC between 16 and 32µgmL –1 for FLU, 0.25–0.5µgmL –1 for ITRA, KETO, and MICO, and 2µgmL –1 for VORI, cR: Isolates with MIC
≥ 64µgmL –1 for FLU, ≥1µgmL –1 for ITRA, KETO, and MICO, ≥ 4µgmL –1 for VORI and ≥2µgmL –1 for AMB.
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Figure 2: SEM images of spray-dried propolis microparticles showing the outer topology: (a) original magniﬁcation ×1000; (b) original
magniﬁcation ×2000.
albicansshowedresistanceforITRA,KETOandMICO(29.0,
48.4, and 16.1%), but all were sensitive or dose-dependent
susceptibility for AMB. More speciﬁcally, two isolates from
C. parapsilosis,o n eC. guilliermondii and six C. glabrata
were resistant for ITRA. For KETO, nine C. glabrata,ﬁ v e
C. guilliermondii and one C. parapsilosis were resistant, and
for MICO, three C. glabrata and two C. parapsilosis were
resistant.
Figure 3(a) shows that all the yeasts, both C. albicans
and non-C. albicans, were inhibited by PE up to a max-
imal concentration of 1100.63µgmL –1 of TPC (average
of 275.17µgmL –1). Most of the isolates (96.63%, n =
86) were inhibited by PE with concentration of TPC of
550.30µgmL –1. Figure 3(b) shows that all the tested yeasts,
both C. albicans and non-C. albicans, were also inhibited
by PMs up to a maximal concentration of 5570.49µgmL –1
of TPC (average = 696.31µgmL –1). Most of the isolates
(93.26%, n = 83) were inhibited by the PMs with con-
centration of TPC of 1392.62µgm L –1. Just one of the
non-C. albicans,aC. glabrata isolate, required the TPC of
5570.49µgmL –1 in PMs (Figure 3(c)). The positive control
of solvent (alcohol 96◦GL) did not demonstrate any activity
against the yeasts.
All resistant isolates of C. albicans were inhibited by PE
with concentration of TPC from 137.58 to 550.30µgmL –1,
and by PMs from 174.06 to 1392.62µgmL –1 (Figures 3(a)
and 3(b)). Moreover, all resistant isolates of non-C. albicans
wereinhibitedbyPEbetween34.40and1100.63µgmL –1 and
by the PMs between 174.06 and 5570.49µgmL –1 (Figures
3(a), 3(b),a n d3(c)).
4. Discussion
Propolis is a hive product containing chieﬂy beeswax and
plant-derived substances such as resin and volatile com-
pounds. The sample of propolis used in this study was
collected from hives located inside a eucalyptus reserve
surrounded by native forest with a predominance of B.
dracunculifolia. This propolis is classiﬁed as “type BRP”,
a typical propolis from north-west of Paran´ a State, Brazil
[23]. Predominant components of the resin of this type
of propolis are cinnamic acids, chieﬂy compounds bearingEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Cumulative numbers of the susceptibility of 89 yeasts by concentration of total phenolic compounds (µg/mL), expressed for
each observed minimum inhibitory concentration (MIC), to: (a) propolis extractive solution; (b) propolis microparticles; (c) propolis
microparticles for yeast species.
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Figure 4: The hypothetical diagram for comparing the antimicrobial activity of propolis extract and propolis microparticles.6 Evidence-Based Complementary and Alternative Medicine
prenyl groups. Terpenoid compounds, such as sesqui, di
and pentacyclic triterpenoids, have been detected in many,
but not all, samples investigated. Brazilian propolis is a rich
source of phenolic substances and the most of them are
prenylated phenylpropanoids [11, 12, 19, 31, 32]. Phenolic
compounds are identiﬁed as being responsible for anti-
inﬂammatory, antimicrobial and in particular antifungal
actions of propolis [13, 33, 34].
Gelatinmicroparticlescontainingpropoliswereprepared
by spray-drying technique. PE characteristics, composition
of dispersion and spray-drying conditions gave PMs with
good surface and shape characteristics. Size analysis showed
that obtained structures are microparticles. These PMs
characteristics are useful for development of propolis vaginal
dosage form without the high ethanol concentration of PE
[11, 12, 26].
The Folin-Ciocalteau method was used to determine
the TPC in the PE and PMs. Thus, we have used this
method as a criterion just for judging the relative amount
of propolis incorporated into the gelatin particles. More-
over, the obtained propolis encapsulation eﬃciency into
microparticles can be attributed to the nature of the spray-
drying mechanism, which provides high drug loading,
particularly in the case of drying of solutions or well-
stabilized suspensions [11, 35].
The combination of temperature, small space and
humidity provide the beehives with good conditions for
m i c r o b i a lg r o w t h[ 12]. Nevertheless, this does not occur
because of the antimicrobial activity of propolis [13, 24].
The antimicrobial activity is the most popular of the
propolis, being between its biological actions more exten-
sively investigated [16, 36]. The Brazilian propolis produced
where the main botanic source is B. dracunculifolia is
highly recommended by modern herbalists since it displays
microbicidal, anti-inﬂammatory, immunomodulatory and
anti-ulcer properties [37]. Thus, antifungal activity of PE
and PMs was evaluated by microdilution method against
several yeasts isolated from patients with VVC, namely C.
albicans and non-C. albicans. Studies of this kind are relevant
becauseoftheneedofnewtherapeuticalternatives,especially
low-cost, eﬃcient and safe ones, for the treatment of VVC,
considering the few therapeutic options and the resistance
observed for some drugs [38].
Imhof et al. [14] tested PE at concentration of 5% in
women with chronic vaginitis without laboratory deﬁnition
of the causal agent, and concluded that this compound can
be an alternative in these instances. However, the authors
pointed to the need of studies comparing the eﬀects of PE
with classical antimicrobial therapies. In this sense, in the
present study, the in vitro activity of various antifungal drugs
was used as a parameter of comparison with PE and PMs
activity, also in vitro (Table 1).
In relationship to the activity of the antifungal drugs
against the tested yeasts, several isolates showed resistance
and dose-dependent susceptibility for azolics, and some
resistance for AMB. The strains of non-C. albicans showed
more resistance and dose-dependent susceptibility than C.
albicans. However, all the yeasts, both C. albicans and non-C.
albicans, were inhibited by PE and PMs, showing that both
are eﬀective. For PMs, a bigger TPC was necessary than the
PE, which did not alterthe inhibition proﬁle (Figure 3). Sim-
ilar results were shown when propolis extractive solutions
and their respective PMs were tested against oral pathogens
[12]. Considering the PE dryness residue, the PE amount
added to prepare the microparticles and the drug trapping
eﬃciency of PMs, that was not greater than 78.51 ± 2.81%,
the PMs activity was similar to the PE. The hypothetical
diagram is presented in Figure 4. Moreover, the results of
Oliveira et al. [13] showed a high sensitivity to PE against
C. albicans and non-C. albicans isolated from patients with
onychomycoses, evidencing an excellent eﬃcacy.
It could be observed that the PE and PMs have shown
very good results, with small variation, independent of
the species of yeast isolated from VVC. This fact puts
the PMs in a position comparable to classical antifungal
compounds [39]. Even the resistant isolates of C. albicans
and non-C. albicans were inhibited by the PMs, suggesting
an action better than that of antifungal drugs tested. The
presence of these resistant isolates and the high index of
yeasts with dose-dependent susceptibility, especially non-
C. albicans (Figure 3(b)), evidence a decreasing of the
therapeutic expectation toward these antifungals. Studies of
Consolaro et al. [8]a n dF e r r a z ae ta l .[ 3] also found an even
higherincidenceofyeastswithdose-dependentsusceptibility
(45.0 and 51.5%, resp.), but absence of resistance.
S e v e r a ls t u d i e sh a v er e p o r t e dt h a tf r o m2 5t o5 0 %o ft h e
women bearing RVVC show re-incidence 4–6 weeks after
conventional antifungal therapy with azolic compounds,
making the management of this condition quite complicated
[40, 41].
Inconclusion,consideringtheantifungalactivityshowed
by PMs and that the high ethanol concentration is a
disadvantage of PE, this report clearly showed that PMs
arises as a possible agent for the treatment and especially
the prevention of the new symptomatic episode the VVC.
Moreover PMs have the advantage of to be incorporated
in some dosage forms, like vaginal ointments, and to be
administered into the vaginal mucosa more easily and safely.
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